JP2002519434A5 - - Google Patents

Download PDF

Info

Publication number
JP2002519434A5
JP2002519434A5 JP2000558116A JP2000558116A JP2002519434A5 JP 2002519434 A5 JP2002519434 A5 JP 2002519434A5 JP 2000558116 A JP2000558116 A JP 2000558116A JP 2000558116 A JP2000558116 A JP 2000558116A JP 2002519434 A5 JP2002519434 A5 JP 2002519434A5
Authority
JP
Japan
Prior art keywords
thr
coome
cooh
phenyl
mebmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000558116A
Other languages
English (en)
Japanese (ja)
Other versions
JP4350898B2 (ja
JP2002519434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB1999/001232 external-priority patent/WO2000001715A1/fr
Publication of JP2002519434A publication Critical patent/JP2002519434A/ja
Publication of JP2002519434A5 publication Critical patent/JP2002519434A5/ja
Application granted granted Critical
Publication of JP4350898B2 publication Critical patent/JP4350898B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000558116A 1998-07-01 1999-06-30 活性の特徴が改善された新規のシクロスポリン Expired - Lifetime JP4350898B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1405/98 1998-07-01
CH140598 1998-07-01
PCT/IB1999/001232 WO2000001715A1 (fr) 1998-07-01 1999-06-30 Nouvelle cyclosporine ayant un profil d'activite ameliore

Publications (3)

Publication Number Publication Date
JP2002519434A JP2002519434A (ja) 2002-07-02
JP2002519434A5 true JP2002519434A5 (enExample) 2008-04-24
JP4350898B2 JP4350898B2 (ja) 2009-10-21

Family

ID=4209677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558116A Expired - Lifetime JP4350898B2 (ja) 1998-07-01 1999-06-30 活性の特徴が改善された新規のシクロスポリン

Country Status (14)

Country Link
US (2) USRE40987E1 (enExample)
EP (1) EP1091975B1 (enExample)
JP (1) JP4350898B2 (enExample)
CN (1) CN1218958C (enExample)
AT (1) ATE312843T1 (enExample)
AU (1) AU759480B2 (enExample)
BR (1) BR9911724A (enExample)
CA (1) CA2335903C (enExample)
DE (1) DE69928938T2 (enExample)
DK (1) DK1091975T3 (enExample)
ES (1) ES2255275T3 (enExample)
MX (1) MXPA00013019A (enExample)
PT (1) PT1091975E (enExample)
WO (1) WO2000001715A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255275T3 (es) 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
DE60028936T2 (de) 1999-02-05 2007-01-11 Debiopharm S.A. Cyclosporin-derivate und verfahren zu deren herstellung
ES2256450T3 (es) 2001-04-20 2006-07-16 Debiopharm S.A. Ciclosporina modificada utilizable como profarmaco y su uso.
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20060035821A1 (en) * 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
EP1793844B1 (en) * 2004-10-01 2010-12-08 Debiopharm S.A. Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
EP1802650B1 (en) * 2004-10-01 2011-10-26 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
ES2387682T3 (es) 2005-01-10 2012-09-28 Debiopharm S.A. Utilización de un undecapéptido cíclico para la preparación de un medicamento administrable durante situaciones isquémicas miocárdicas
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
PT1957518E (pt) 2005-10-26 2016-02-26 Astellas Pharma Inc Novos compostos peptídicos cíclicos
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2007141395A1 (fr) * 2006-06-02 2007-12-13 Claude Annie Perrichon Gestion des electrons actifs
CN101108178B (zh) * 2006-07-20 2010-09-15 复旦大学 一种亲环素a抑制剂在制备抗艾滋病药物中的应用
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
AU2008204344B2 (en) * 2007-01-04 2013-01-31 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
JP5459545B2 (ja) 2007-05-02 2014-04-02 アステラス製薬株式会社 新規環状ペプチド化合物
NZ584356A (en) 2007-09-26 2011-10-28 Univ Oregon Health & Science Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
JP5780969B2 (ja) * 2008-12-31 2015-09-16 サイネクシス,インコーポレーテッド シクロスポリンaの誘導体
EP2391376A4 (en) * 2009-01-30 2012-08-01 Enanta Pharm Inc ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
US8802666B2 (en) 2009-12-21 2014-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitors of cyclophilins and uses thereof
CN103153329A (zh) 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012037485A2 (en) * 2010-09-16 2012-03-22 1The Johns Hopkins University Methods of inhibiting alphavirus replication and treating alphavirus infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN107496902B (zh) 2010-12-15 2022-01-18 康卓维尔制药公司 在氨基酸1和3位修改的环孢菌素类似分子
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
MX2016002458A (es) 2013-08-26 2016-08-08 Enanta Pharm Inc Análogos novedosos de ciclosporina para prevenir o tratar la infección por hepatitis c.
CN104744570A (zh) * 2013-12-31 2015-07-01 深圳先进技术研究院 一种环孢菌素的合成方法
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20230149504A1 (en) 2020-04-06 2023-05-18 Debiopharm International Sa Alisporivir for use in human viral infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (enExample) 1975-11-04 1979-12-28 Sandoz Ag
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
AU548156B2 (en) 1980-02-14 1985-11-28 Novartis Ag Cyclo sporin
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
DE3047662C2 (de) 1980-12-18 1985-02-21 Karl M. Reich Maschinenfabrik GmbH, 7440 Nürtingen Puffersystem bei Einschlaggeräten
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JPH074269B2 (ja) 1984-10-04 1995-01-25 サンド・アクチエンゲゼルシャフト シクロスポリン類に対するモノクロ−ナル抗体
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
ATE148469T1 (de) 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
ATE209216T1 (de) 1995-07-17 2001-12-15 Chem Ag C Cyclosporin-derivate mit anti-hiv-wirkung
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2255275T3 (es) 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7439277B2 (en) 2005-05-19 2008-10-21 Fina Technology, Inc. In-situ preparation of hydroperoxide functionalized rubber

Similar Documents

Publication Publication Date Title
JP2002519434A5 (enExample)
EP1159964A3 (en) Compositions and methods for stimulating gastrointestinal motility
EP1772142A3 (en) Organic compounds
JP2003531118A5 (enExample)
JP2002510633A5 (enExample)
WO2002020466B1 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
JP2002519425A5 (enExample)
JP2002533472A5 (enExample)
JP2003501474A5 (enExample)
JP2003528808A5 (enExample)
JP2001526218A5 (enExample)
JP2003519228A5 (enExample)
JP2003509349A5 (enExample)
JP2003512474A5 (enExample)
JP2005520779A5 (enExample)
RU2002105377A (ru) Ксенон-антагонист nmda
JP2003502367A5 (enExample)
JP2003520208A5 (enExample)
EP1166778A3 (en) The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
JP2004500325A5 (enExample)
JP2002522501A5 (enExample)
JP2002506864A5 (enExample)
EP1175900A3 (en) Use of growth hormone secretagogues for improvement of fucnctional health status
JP2002520286A5 (enExample)
JP2009517411A5 (enExample)